Eighteen patients were treated with 70 mg tissue plasminogen activator (t-PA) intravenously after the onset of acute severe cerebral ischemia: 10 suffered from vertebrobasilar occlusive disease and 8 had carotid territory strokes. In the former, reperfusion rates were poor (4/10) which was associated with a fatal clinical outcome in 7. In patients with internal carotid and middle cerebral artery occlusions, reperfusion rates were similarly low (3/7), 3 patients died from ischemia independent from the observed perfusional state and 1 suffered a fatal hemorrhage after infusion of less than 25 mg t-PA. Since many of the patients particularly with vertebrobasilar disease were somnolent or stuporous, an unfavorable delay between thrombosis and thrombolysis was suggested - in addition, since infarction was obvious on CT. In all, the dosage selected seemed to be too low to be efficient. Further investigations are required to test the benefit of earlier treatment (<4 h) with higher dosages of t-PA.

Keywords:
Thrombolysis, Stroke, Plasminogen activator
This content is only available via PDF.
© 1991 S. Karger AG, Basel
1991
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.